Amgen's biggest product, based on its 2023 revenue, is Prolia.
Prolia is a key medication in Amgen's portfolio, primarily used to treat osteoporosis in postmenopausal women at high risk of fracture, as well as bone loss in men with prostate cancer and women with breast cancer receiving certain treatments. In 2023, Prolia generated approximately 4.05 billion U.S. dollars in revenue for Amgen, solidifying its position as the company's top-performing product.
Amgen is a prominent U.S.-based multinational biopharmaceutical company, with its headquarters located in Thousand Oaks, California.
Key Product Performance
While Amgen has a diverse range of innovative medicines, Prolia stands out in terms of revenue generation.
| Product | 2023 Revenue (USD) | Primary Indication |
|---|---|---|
| Prolia | 4.05 billion | Osteoporosis, Bone Loss |
For more information about Amgen and its product pipeline, you can visit the official Amgen website.
